Skip to main content
GutCited

Saccharomyces boulardii cho Antibiotic-Associated Diarrhea (AAD)

A Bằng chứng Nhiều thử nghiệm lâm sàng lớn liên tục cho thấy những lợi ích đáng kể.

Multiple meta-analyses show S. boulardii reduces AAD risk by 47-53% (RR 0.47). Most studied probiotic for AAD prevention with consistent positive results across antibiotic classes.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

Kết luận

Multiple meta-analyses show S. boulardii reduces AAD risk by 47-53% (RR 0.47). Most studied probiotic for AAD prevention with consistent positive results across antibiotic classes.

Key Study Findings

Observational Study n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None so với: None Outcome: Probiotic prescribing habits of Italian PCPs Hiệu quả: L. rhamnosus GG used by 91.8% None

Đối tượng nghiên cứu: Italian primary care pediatricians

Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None so với: None Outcome: None Hiệu quả: None None

Đối tượng nghiên cứu: Pediatric population

Review
Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping …
Dose: None so với: None Outcome: None Hiệu quả: None None

Đối tượng nghiên cứu: scoping review of intestinal dysbiosis definition, symptoms, and probiotic adjuvant therapy in adults and children

Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None so với: None Outcome: Clinical guideline recommendations for pediatric GI Hiệu quả: None None

Đối tượng nghiên cứu: Pediatric patients with GI disorders

Review
Clostridioides difficile Infections: Prevention and Treatment Strategies.
Dose: None so với: None Outcome: C. difficile infection treatment outcomes Hiệu quả: None None

Đối tượng nghiên cứu: Patients with C. difficile infection

Randomized Controlled Trial n=47 1 weeks
[A prospective randomized controlled study on probiotics for the prevention of antibiotic-associated diarrhea in infants …
Dose: None so với: Control Outcome: Gut microbiota composition Hiệu quả: None P<0.017

Đối tượng nghiên cứu: Children

Key Statistics

25

Nghiên cứu

5000

Người tham gia

↑

Positive

A

Xếp hạng

Referenced Papers

Advances in experimental … 2024 2 trích dẫn
Archivos argentinos de … 2022 23 trích dẫn
Advances in experimental … 2019 17 trích dẫn
The American journal … 2018 46 trích dẫn
Journal of pediatric … 2016 233 trích dẫn
Clinical and experimental … 2016 82 trích dẫn
Digestive diseases (Basel, … 2016 37 trích dẫn
The Cochrane database … 2015 233 trích dẫn
Journal of clinical … 2015 35 trích dẫn
Expert opinion on … 2014 57 trích dẫn
Journal of clinical … 2011 432 trích dẫn
World journal of … 2010 512 trích dẫn
Journal for specialists … 2010 22 trích dẫn
American journal of … 2010
European journal of … 2009 91 trích dẫn
Current opinion in … 2009 82 trích dẫn
Advances in biochemical … 2008 535 trích dẫn
American family physician 2008
The Journal of … 2007 265 trích dẫn
The American journal … 2001 648 trích dẫn
International journal of … 2000 181 trích dẫn
Clinical infectious diseases … 1998 346 trích dẫn

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Liều lượng thường dùng

general:
250-500 mg/day (equivalent to 5-10 billion CFU)
aadprevention:
500 mg/day (start with antibiotic, continue 7 days after)
cdiffprevention:
500 mg twice daily as adjunct to standard therapy
travelersdiarrhea:
250-500 mg/day starting 5 days before travel

Giới hạn trên: Well-tolerated up to 1,000 mg/day in clinical trials

Liều lượng đã nghiên cứu

Liều lượng Thời gian Hiệu quả N
None -- Mixed 279
None -- Mixed --
None -- Positive --
None -- Positive --
None -- Positive --
None 1 weeks Positive 47
None 20 weeks Positive 564
None -- Positive --

Thời điểm dùng tốt nhất: Can be taken with or without food; space 2 hours from antifungals

Safety & Side Effects

Tác dụng phụ đã được báo cáo

  • ⚠ Mild gas and bloating
  • ⚠ Rare: fungemia in critically ill patients with central venous catheters
  • ⚠ Thirst (yeast may increase water requirements)
  • ⚠ Very rare: potential environmental contamination risk in ICU settings

Tương tác đã biết

  • ● Antifungal medications (may kill S. boulardii, reducing effectiveness)
  • ● Monoamine oxidase inhibitors (S. boulardii contains tyramine)
  • ● Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)

Mức hấp thụ tối đa cho phép: Well-tolerated up to 1,000 mg/day in clinical trials

Luôn tham khảo ý kiến bác sĩ trước khi bắt đầu sử dụng bất kỳ thực phẩm bổ sung nào.Luôn tham khảo ý kiến chuyên gia y tế trước khi sử dụng bất kỳ thực phẩm chức năng nào.

Frequently Asked Questions

Does Saccharomyces boulardii help with Antibiotic-Associated Diarrhea (AAD)?
Based on 25 studies with 5,000 participants, there is strong evidence from multiple clinical trials that Saccharomyces boulardii may support Antibiotic-Associated Diarrhea (AAD) management. Our evidence grade is A (Strong Evidence).
How much Saccharomyces boulardii should I take for Antibiotic-Associated Diarrhea (AAD)?
Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Saccharomyces boulardii?
Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Saccharomyces boulardii and Antibiotic-Associated Diarrhea (AAD)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 25 peer-reviewed studies with 5,000 total participants. The overall direction of effect is positive.

Các thành phần khác cho Antibiotic-Associated Diarrhea (AAD)

Saccharomyces boulardii cho các tình trạng khác

References

  1. [1] Ailim Margarita Carías Domínguez et al.. Probiotics Antimicrob Proteins. 2025. Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping Review. doi:10.1007/s12602-024-10353-w PubMed
  2. [2] Kok-Ann Gwee et al.. J Gastroenterol Hepatol. 2025. The evidence for probiotics in the treatment of digestive disorders in the pediatric population. doi:10.1111/jgh.16809 PubMed
  3. [3] Giacomo Biasucci et al.. Antibiotics (Basel). 2025. Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care Pediatricians. doi:10.3390/antibiotics14060577 PubMed
  4. [4] Sylvia Cruchet et al.. Bol Med Hosp Infant Mex. 2025. Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and nutrition: probiotics chapter. doi:10.24875/BMHIM.M25000043 PubMed
  5. [5] Vladimir Hodzhev et al.. Open Forum Infect Dis. 2024. High-dose Probiotic Mix of Lactobacillus spp., Bifidobacterium spp., Bacillus coagulans, and Saccharomyces boulardii to Prevent Antibiotic-associated Diarrhea in Adults: A … doi:10.1093/ofid/ofae615 PubMed
  6. [6] Su-Wei Zhang et al.. Zhongguo Dang Dai Er Ke Za Zhi. 2024. [A prospective randomized controlled study on probiotics for the prevention of antibiotic-associated diarrhea in infants and young children]. doi:10.7499/j.issn.1008-8830.2401129 PubMed
  7. [7] Elvira Ingrid Levy et al.. Adv Exp Med Biol. 2024. Clostridioides difficile Infections: Prevention and Treatment Strategies. doi:10.1007/978-3-031-58572-2_11 PubMed
  8. [8] Dhanasekhar Kesavelu et al.. Ther Adv Infect Dis. 2023. Current understanding of antibiotic-associated dysbiosis and approaches for its management. doi:10.1177/20499361231154443 PubMed
  9. [9] Qingrui Yang et al.. Front Pharmacol. 2023. Overview of systematic reviews of probiotics in the prevention and treatment of antibiotic-associated diarrhea in children. doi:10.3389/fphar.2023.1153070 PubMed
  10. [10] Sarath Gopalan et al.. Cureus. 2023. Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review. doi:10.7759/cureus.46314 PubMed
  11. [11] Nyier W Doar et al.. Cureus. 2023. Qualitative Analysis of the Efficacy of Probiotic Strains in the Prevention of Antibiotic-Associated Diarrhea. doi:10.7759/cureus.40261 PubMed
  12. [12] Amarender S Puri. J Assoc Physicians India. 2023. The Role of Yeast Probiotics in Gastrointestinal Conditions: An Overview. doi:10.5005/japi-11001-0235 PubMed
  13. [13] Christian Boggio Marzet et al.. Arch Argent Pediatr. 2022. Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG. doi:10.5546/aap.2022.eng.e1 PubMed
  14. [14] Dorota Czerucka et al.. World J Gastroenterol. 2019. Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections. doi:10.3748/wjg.v25.i18.2188 PubMed
  15. [15] Meltem Dinleyici et al.. Adv Exp Med Biol. 2019. Clostridium difficile Colitis Prevention and Treatment. doi:10.1007/5584_2018_322 PubMed
  16. [16] Lynne V McFarland et al.. Front Med (Lausanne). 2018. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. doi:10.3389/fmed.2018.00124 PubMed
  17. [17] Jason C Sniffen et al.. PLoS One. 2018. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. doi:10.1371/journal.pone.0209205 PubMed
  18. [18] Cecilia Mantegazza et al.. Pharmacol Res. 2018. Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. doi:10.1016/j.phrs.2017.08.001 PubMed
  19. [19] Jie Chen et al.. World J Pediatr. 2018. Chinese clinical practice guidelines for acute infectious diarrhea in children. doi:10.1007/s12519-018-0190-2 PubMed
  20. [20] Ronald L Koretz. Am J Gastroenterol. 2018. Probiotics in Gastroenterology: How Pro Is the Evidence in Adults? doi:10.1038/s41395-018-0138-0 PubMed
  21. [21] Donald Cameron et al.. World J Gastroenterol. 2017. Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. doi:10.3748/wjg.v23.i45.7952 PubMed
  22. [22] Hania Szajewska et al.. J Pediatr Gastroenterol Nutr. 2016. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. doi:10.1097/MPG.0000000000001081 PubMed
  23. [23] Heike Stier et al.. Clin Exp Gastroenterol. 2016. Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system. doi:10.2147/CEG.S111003 PubMed
  24. [24] Stephan Ehrhardt et al.. Open Forum Infect Dis. 2016. Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. doi:10.1093/ofid/ofw011 PubMed
  25. [25] Hania Szajewska et al.. Dig Dis. 2016. Probiotic Bacterial and Fungal Strains: Claims with Evidence. doi:10.1159/000443359 PubMed
  26. [26] Joshua Z Goldenberg et al.. Cochrane Database Syst Rev. 2015. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. doi:10.1002/14651858.CD004827.pub4 PubMed
  27. [27] Lynne V McFarland. Antibiotics (Basel). 2015. Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. doi:10.3390/antibiotics4020160 PubMed
  28. [28] Alfredo Guarino et al.. J Clin Gastroenterol. 2015. Probiotics for Prevention and Treatment of Diarrhea. doi:10.1097/MCG.0000000000000349 PubMed
  29. [29] Danielle Barnes et al.. Nutr Clin Pract. 2015. Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. doi:10.1177/0884533615610081 PubMed
  30. [30] Carlos Pérez. Nutr Hosp. 2015. [Probiotics for the treating acute diarrhea and preventing antibiotic-associated diarrhea in children]. doi:10.3305/nh.2015.31.sup1.8709 PubMed
  31. [31] Ener Cagri Dinleyici et al.. Expert Opin Biol Ther. 2014. Saccharomyces boulardii CNCM I-745 in different clinical conditions. doi:10.1517/14712598.2014.937419 PubMed
  32. [32] George Micklefield. MMW Fortschr Med. 2014. [Saccharomyces boulardii in the treatment and prevention of antibiotic-associated diarrhea]. PubMed
  33. [33] G Micklefield. MMW Fortschr Med. 2014. [Saccharomyces boulardii in the treatment and prevention of antibiotic-associated diarrhea]. PubMed
  34. [34] Pietro Pozzoni et al.. Am J Gastroenterol. 2012. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. doi:10.1038/ajg.2012.56 PubMed
  35. [35] Maria Assunta Zocco et al.. Am J Gastroenterol. 2012. Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use. doi:10.1038/ajg.2012.222 PubMed
  36. [36] Ewa Kamińska. Med Wieku Rozwoj. 2012. [Effectiveness and safety of probiotics in children on the basis of clinical trials]. PubMed
  37. [37] Stefano Guandalini. J Clin Gastroenterol. 2011. Probiotics for prevention and treatment of diarrhea. doi:10.1097/MCG.0b013e3182257e98 PubMed
  38. [38] Lynne V McFarland. World J Gastroenterol. 2010. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. doi:10.3748/wjg.v16.i18.2202 PubMed
  39. [39] Kathleen Jones. J Spec Pediatr Nurs. 2010. Probiotics: preventing antibiotic-associated diarrhea. doi:10.1111/j.1744-6155.2010.00231.x PubMed
  40. [40] Nancy Toedter Williams. Am J Health Syst Pharm. 2010. Probiotics. doi:10.2146/ajhp090168 PubMed
  41. [41] Yvan Vandenplas et al.. Eur J Pediatr. 2009. Saccharomyces boulardii in childhood. doi:10.1007/s00431-008-0879-7 PubMed
  42. [42] Alfredo Guarino et al.. Curr Opin Gastroenterol. 2009. Probiotics as prevention and treatment for diarrhea. doi:10.1097/MOG.0b013e32831b4455 PubMed
  43. [43] Michael de Vrese et al.. Adv Biochem Eng Biotechnol. 2008. Probiotics, prebiotics, and synbiotics. doi:10.1007/10_2008_097 PubMed
  44. [44] Shira Idit Doron et al.. J Clin Gastroenterol. 2008. Probiotics for prevention of antibiotic-associated diarrhea. doi:10.1097/MCG.0b013e3181618ab7 PubMed
  45. [45] Benjamin Kligler et al.. Am Fam Physician. 2008. Probiotics. PubMed
  46. [46] Michael de Vrese et al.. J Nutr. 2007. Probiotics and prebiotics: effects on diarrhea. doi:10.1093/jn/137.3.803S PubMed
  47. [47] B C Johnston et al.. Cochrane Database Syst Rev. 2007. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. doi:10.1002/14651858.CD004827.pub2 PubMed
  48. [48] Lynne V McFarland. Am J Gastroenterol. 2006. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. doi:10.1111/j.1572-0241.2006.00465.x PubMed
  49. [49] Bradley C Johnston et al.. CMAJ. 2006. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. doi:10.1503/cmaj.051603 PubMed
  50. [50] Jeffry A Katz. J Clin Gastroenterol. 2006. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. doi:10.1097/00004836-200603000-00017 PubMed
  51. [51] Mehmet Can et al.. Med Sci Monit. 2006. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. PubMed
  52. [52] P R Marteau et al.. Am J Clin Nutr. 2001. Protection from gastrointestinal diseases with the use of probiotics. doi:10.1093/ajcn/73.2.430s PubMed
  53. [53] E Bergogne-Bérézin. Int J Antimicrob Agents. 2000. Treatment and prevention of antibiotic associated diarrhea. doi:10.1016/s0924-8579(00)00293-4 PubMed
  54. [54] C Högenauer et al.. Clin Infect Dis. 1998. Mechanisms and management of antibiotic-associated diarrhea. doi:10.1086/514958 PubMed
  55. [55] L V McFarland et al.. Anaerobe. 1997. Pharmaceutical probiotics for the treatment of anaerobic and other infections. doi:10.1006/anae.1996.0062 PubMed
  56. [56] C M Surawicz et al.. Gastroenterology. 1989. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. doi:10.1016/0016-5085(89)91613-2 PubMed

Tuyên bố miễn trừ FDA: Các tuyên bố này chưa được Cục Quản lý Thực phẩm và Dược phẩm (FDA) đánh giá. Các sản phẩm và thông tin trên trang web này không nhằm mục đích chẩn đoán, điều trị, chữa bệnh hoặc phòng ngừa bất kỳ bệnh nào. Xếp hạng bằng chứng được trình bày dựa trên phân tích của chúng tôi về nghiên cứu đã bình duyệt được công bố và không cấu thành tư vấn y khoa. Luôn tham khảo ý kiến chuyên gia y tế trước khi bắt đầu bất kỳ chế độ thực phẩm chức năng nào.